Pediatric Compounding Conundrums: Just Keep Swimming

NOTE: This session is part of the Live Intensive Studies and Clinical Sessions packages. All attendees may attend these thought-provoking and highly educational sessions. However, if you are board-certified, you must purchase the package(s) for your specialty to receive the recertification assessment and claim the recertification credit.

Due to continued challenges surrounding the availability of suitable manufactured dosage forms and doses for pediatric patients, pharmacists must constantly evaluate the available options and use compounding to meet the needs of these patients. Using a “choose your adventure” format, this session will provide insight into some of the challenges for compounding pediatric patient formulations and highlight opportunities and challenges related to this type of compounding, including managing 12-hour beyond-use dates (BUDs) for stock solutions (a new requirement with USP <797> updates), understanding the limits of IV automation and systems and their impact on compounding processes, managing dilutions of products with limited stability information, and determining the appropriate BUD for blinatumomab after recent package insert changes.

This activity is approved for Board-Certified Sterile Compounding Pharmacist (BCSCP) recertification credit.